Anticancer potential of benzo[b]thiophene functionalized thiosemicarbazone ligands and their organoruthenium complexes
As novel promising anticancer candidates, the piano-stool type complexes of ruthenium, [RuCl(η -p-cymene)(N,S-L )]PF , K - , were synthesized from the reaction of the substituted benzo[b]thiophene based thiosemicarbazone ligands (L ) with [{RuCl(η -p-cymene)} (μ-Cl) ]. All complexes were fully chara...
Gespeichert in:
Veröffentlicht in: | Journal of biological inorganic chemistry 2024-12 |
---|---|
Hauptverfasser: | , , , , |
Format: | Artikel |
Sprache: | eng |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | As novel promising anticancer candidates, the piano-stool type complexes of ruthenium, [RuCl(η
-p-cymene)(N,S-L
)]PF
, K
-
, were synthesized from the reaction of the substituted benzo[b]thiophene based thiosemicarbazone ligands (L
) with [{RuCl(η
-p-cymene)}
(μ-Cl)
]. All complexes were fully characterized using elemental analysis, and spectroscopic methods such as FT-IR and
H NMR. The molecular masses of the complexes were proved by MALDI-TOF analysis. Single crystal X-ray diffraction study was employed in the structural elucidation of complex K
which shows a distorted octahedral geometry around the Ru(II) ion. Furthermore, spectroscopic methods revealed that in all complexes the ligands are coordinated to the metal center in neutral thione form via N, S donors. In this study, the effect of all ligands, complexes and commercial drugs with a different concentration on the viability of OVCAR-3, A2780 and OSE cells were compared. In this comparison, the cytotoxicity of ruthenium (II) complexes on two ovarian cancer cell lines (human A2780 and human OVCAR-3) was evaluated. For this purpose, the resazurin assay was performed. Based on our studies, complex K
showed the highest toxicity against OVCAR-3 and A2780 cells. The cytotoxic effect of K
was found to be higher than that of the commercial anticancer agents Oxalpin and Carbodex, 1.8-34.7-fold for OVCAR-3 cells and 1.9-11.8-fold for A2780 cells, respectively. These results provide insight into the potential of ruthenium (II) complexes as a cytotoxic agent for the treatment of ovarian cancer, particularly for primary tumors. |
---|---|
ISSN: | 1432-1327 1432-1327 |
DOI: | 10.1007/s00775-024-02090-w |